Lisraya (Brepocitinib)

Brepocitinib is a medicine used to treat dermatomyositis, a disease that causes muscle weakness and skin rashes. It works by calming the parts of the immune system that attack the muscles and skin. It is taken as a pill.

Brand names:Lisraya
Medication

What people taking Lisraya (Brepocitinib) report

Every report comes from a Lived member, sent anonymously.

Have you tried Lisraya (Brepocitinib) for Dermatomyositis?

NameHow it went

About Lisraya (Brepocitinib)

What It's For

Brepocitinib, sold under the brand name Lisraya, is a prescription tablet for adults with dermatomyositis. Dermatomyositis is an autoimmune disease, meaning the immune system attacks the body's own tissue. It causes muscle weakness along with a skin rash, and it can bring tiredness after walking or standing, tripping or falls, and sometimes trouble swallowing or breathing. The FDA approved Lisraya in 2026. It belongs to a group of medicines called JAK (Janus kinase) inhibitors, which calm an overactive immune system. In the study that led to its approval, most people kept taking their usual dermatomyositis treatments, such as corticosteroids (steroid medicines like prednisone) or other immune-suppressing medicines, and added brepocitinib on top.

How It Works

Immune cells coordinate inflammation with cytokines, chemical messengers that switch on activity in other cells. When a cytokine attaches to a cell, enzymes inside it called Janus kinases (JAKs) pass the signal along and turn on genes that keep the inflammatory response going. TYK2 (tyrosine kinase 2) is one member of this enzyme family. Brepocitinib blocks mainly TYK2 and JAK1, which dampens several of these inflammatory signals at once and reduces the immune activity directed at muscle and skin. It is not known exactly which of these signals matter most for its benefit. The same dampening of the immune system is also the main source of its risks, especially infection.

Dosage & Administration

Brepocitinib is taken by mouth as one 30 mg tablet once a day, with or without food. This is the only approved dose; a lower 15 mg dose was studied but is not approved. Before starting, the care team usually checks for tuberculosis (TB) and hepatitis B and C, runs a complete blood count and liver and kidney tests, confirms that anyone who could become pregnant is not pregnant, and brings vaccines up to date. Active hepatitis B or C, very low white blood cell or red blood cell counts, and severe liver or kidney disease are reasons to avoid it. Treatment is paused during a serious infection until it is treated or clears. The prescriber may also pause it if blood counts fall too low or if liver injury from the medicine is suspected, then restart once these settle.

Side Effects

In the main year-long study, infections were the most common side effects, especially colds and other upper respiratory infections, urinary tract infections, bronchitis and flu. Other common effects were headache, tiredness, nausea, diarrhea, joint aches, back pain, acne and falls. Infections of any kind were more frequent than with placebo, affecting 69% of people taking brepocitinib compared with 57% on placebo. Serious infections, mainly pneumonia and sepsis (a dangerous body-wide reaction to infection), affected about 1 in 10 people taking brepocitinib, compared with about 1 in 100 on placebo. Shingles, a painful blistering rash caused by the chickenpox virus waking up again, occurred in about 5% and was more frequent in people 65 and older, who also had more serious side effects overall. Contact the care team right away about fever, chills, a new cough, burning with urination, a new painful rash or other signs of infection, since treatment may need to be paused. Blood tests can also change, with lower white blood cell counts, anemia, raised liver enzymes and higher cholesterol. These usually cause no symptoms, which is why regular testing matters.

Interactions & Warnings

Lisraya carries a boxed warning, the FDA's most prominent safety warning, shared with other JAK inhibitors. It warns of serious infections (described under Side Effects), cancer, heart attack and stroke, and blood clots in the legs, lungs or arteries, which can be fatal. Cancers, heart events and clots have occurred in people taking brepocitinib. Much of the concern comes from a large study of another JAK inhibitor in people aged 50 or older with rheumatoid arthritis and at least one heart risk factor, which found higher rates of death, cancer (including lymphoma, and lung cancer in smokers), heart events and clots than with tumor necrosis factor (TNF) blockers, a different kind of arthritis medicine. In practice, this means the decision to start weighs these risks most carefully for current and past smokers and for people with heart disease or heart risk factors, a past blood clot, or a past or current cancer. As part of guarding against skin cancer, limiting sun and tanning-bed exposure with protective clothing and broad-spectrum sunscreen is advised, with regular skin checks for people at higher risk of skin cancer. A few symptoms need action right away. Get emergency care for chest pain, sudden weakness or numbness on one side of the body, trouble speaking, sudden shortness of breath, or a painful, swollen leg, which can signal a heart attack, stroke or blood clot. Stop the medicine and get immediate medical help for a serious allergic reaction. Get medical care right away for new belly pain, especially with fever, chills, nausea or vomiting, because JAK inhibitors can cause a tear in the stomach or bowel. That risk is higher after diverticulitis or with NSAIDs (pain relievers such as ibuprofen) or corticosteroids, which many people with dermatomyositis take. Brepocitinib is not meant to be combined with other JAK inhibitors, such as tofacitinib (Xeljanz) or upadacitinib (Rinvoq), with TYK2 inhibitors such as deucravacitinib (Sotyktu), a psoriasis medicine, or with biologic medicines that target the immune system, such as rituximab (Rituxan) or adalimumab (Humira). Live vaccines, such as the measles, mumps and rubella (MMR) vaccine and the chickenpox vaccine, should be avoided just before and during treatment, so tell anyone giving a vaccine that you take it. Smoking lowers the amount of brepocitinib in the blood and may make it less effective. It can also raise blood levels of some other medicines, so the pharmacist should see a full medicine list. People with diabetes can develop low blood sugar, may need to check their glucose more often, and should tell the care team about episodes of low blood sugar. Animal studies suggest brepocitinib may harm a developing baby. People who could become pregnant should use effective contraception during treatment and for 3 days after the last dose, and breastfeeding is not recommended for the same period. Pregnancy plans are worth discussing early.

What to Expect

In the approval study, people taking brepocitinib for a year improved more than those on placebo on a combined score covering muscle strength, skin and other symptoms, daily function, and doctor and patient ratings. About half (48%) reached what researchers call major improvement, a score of at least 60 on the study's 0 to 100 combined scale, compared with about a quarter (26%) on placebo. Skin redness eased, and more people were able to bring their steroid dose down to a low level or stop it. Not everyone responds this well, and the study's main result was measured after a full year, so the care team will judge response over months rather than weeks. Blood tests continue throughout treatment to check blood counts, liver enzymes and cholesterol, with cholesterol usually rechecked about 12 weeks after starting. Because dermatomyositis can itself raise some liver tests, the team also checks GGT (gamma-glutamyl transferase), a liver enzyme that helps tell liver injury from muscle inflammation. Brepocitinib was approved in 2026, so experience with it outside clinical trials is still limited.

Questions to Ask Your Doctor

  1. 1.Why is brepocitinib a good fit for me compared with adjusting my current dermatomyositis treatment?
  2. 2.Given my heart risk factors, smoking history or any past cancer, how do the boxed warning risks apply to me?
  3. 3.Which vaccines should I get before starting, and which should I avoid while taking it?
  4. 4.Which blood tests will I need, how often, and what results would mean pausing treatment?
  5. 5.If it works, how and when might we lower my steroid dose, and how long would I stay on brepocitinib?

Last reviewed • Oct 2026

Educational content, not medical advice.